WSJ Buy Side is The Wall Street Journal’s research and commerce team. Our commerce content is distinct from our newsroom coverage. We earn a commission from some links in our articles. Learn more.

Illustration of a university building in front of dollar bills partially obscuring Donald Trump’s face. In response to indirect cost rate caps, higher education organizations created a new model that ...

Tire pressure sensors and reset procedures can can vary from one vehicle to the next.

If you’re in the market for a new set of wheels, the choice between leasing and owning could make or break your budget, both monthly and in the long term. Which is right for you? There is no single ...

A major change to Social Security is coming for recipients who get their benefits sent to a debit card. Recipients who use the Direct Express debit cards have a change coming, too. The Treasury ...

Visual Studio Code 1.126 adds session-level Copilot cost information, expanding cost visibility beyond individual chat turns. The update follows recent VS Code additions including a Copilot spend ...

A sweeping proposed rule on federal grantmaking contains subtle efforts to reduce federal spending on indirect costs, despite the White House emphasizing that the rule would leave the current rates ...

Efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib vs TACE alone in the treatment of non-resectable hepatocellular carcinoma: A systematic review and meta-analysis. (Bucher; ...

MarketScan data showed 97% of drug–form–strength combinations were available via MCCPDC; savings estimates assumed a $5.25 shipping fee per drug, likely understating net savings. Cost advantages ...

New York Post may receive revenue from affiliate and advertising partnerships for sharing this content and/or when you make a purchase. Printing industry analysts estimate that a typical home user ...

NIH recently issued Notice NOT‑OD‑26‑072, which has generated questions about whether NIH indirect cost (F&A) rules have changed again—and whether there is any adverse impact for Drexel investigators.

Autologous and allogeneic cell therapies are establishing viable clinical pathways but cannot be manufactured cost-effectively at scale. Manufacturing natural killer (NK) cell therapies, and possibly ...